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Abstract
Background: Patients requiring ventral hernia (VH) repair during perioperative chemotherapy have a higher risk for
post-operative complications. The aim of the study was to perform a case-controlled analysis in patients undergoing
chemotherapy who underwent VH repair using biological mesh or synthetic mesh.
Methods: From January 2013 to December 2015, 32 patients, within 8 weeks from chemotherapy administration, were
treated electively for VH repair using a biological mesh (BIOMESH). A control group (CG) receiving chemotherapy
within the same time interval and treated with synthetic meshes was selected. There were no differences regarding
sex, age, American Society of Anesthesiologists (ASA) score III, BMI, and size of the defect. Morbidity, type of
complications, and recurrence rate were investigated and compared between the two groups.
Results: In the BIOMESH group, eight patients (25 %) experienced complications. Wound dehiscence occurred in
four (12.5 %) patients and was treated conservatively. Only three small seromas not requiring treatment were
observed. The CG presented a higher mean Clavien-Dindo complication grade (1.94 ± 0.44 vs 1.63 ± 0.52; p = 0.13)
and a higher incidence of wound dehiscence (n = 9/32, 28.1 % vs n = 4/32, 12.5 %; p = 0.11). Five patients developed
seroma treated by wound drainage. One patient experienced an intra-abdominal collection treated by percutaneous
drainage. At the univariate and multivariate analysis use of traditional mesh, BMI and the ASA III were predictive factors
of post-operative complications. Two patients (6.3 %) developed a VH recurrence only in the CG.
Conclusions: Biological meshes could be considered a valid option to improve post-operative short-term outcomes in
selected high-risk patients undergoing chemotherapy treated for VH repair.
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Background
Post-incisional ventral hernia (VH) is a common compli-
cation after abdominal surgery reaching an incidence
that ranges between 2 and 20% according to the litera-
ture [1–3]. Several factors are related with its presenta-
tion depending on both technical aspects and patient
characteristics; type of abdominal incision, suture mate-
rials, surgical technique, and type of mesh used to repair
the defect are important technical factors to consider as
well as advanced age, high BMI, post-operative septic
complications and corticosteroid treatment [4, 5].
Patients undergoing oncologic surgery have a higher
risk of VH occurrence as a result of several and complex
factors related both to the primitive disease and to the
surgical procedure itself. Moreover, some of these pa-
tients may require VH repair in a short time frame from
perioperative chemotherapy due to symptomatic pres-
entation, increasing the risk of post-operative wound
infection and recurrence; this is probably related to the
immune cells function and thus mesh incorporation that
are known to be suppressed under oncological systemic
treatments [6, 7]. Indeed, according to the Ventral Hernia
Working Group (VHWG) grading system for the assess-
ment of surgical site recurrence risk, every immunosup-
pressed patient is classified as grade 2 as well as patients
with comorbidities [8]. Certainly, the use of synthetic
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meshes could reduce the incidence of VH recurrence,
although the risk of infection limits their use in con-
taminated surgical fields or in high-risk patients [4, 9].
Biologic materials-based meshes (BIOMESH) have re-
cently emerged as a useful option to repair VH in high-
risk patients; these meshes in fact, carry a lower risk of
infection and degrade in septic fields thus avoiding the
necessity of removal [3, 10]. Piazzese et al. in 2004 dem-
onstrated no differences in terms of wound complica-
tions and VH recurrence in liver-transplanted patients
undergoing incisional hernia repair comparing synthetic
mesh with biological mesh [11]. Moreover, in a recent
study, Saied et al. concluded that chemotherapy adminis-
tration did not increase the rate of wound complications
in their series of patients undergoing VH repair with bio-
material mesh [3]. Despite this, no data comparing the use
of synthetic mesh with BIOMESH in high-risk patients
undergoing chemotherapy are available in the literature.
Due to the lack of data, we decided to perform a case-
controlled study concerning high-risk patients undergo-
ing chemotherapy for different malignancies who under-
went VH repair with BIOMESH placement; these cases
were controlled with patients undergoing VH repair using
traditional synthetic mesh. We specifically investigated
rate of complications and VH recurrence.
Methods
From January 2013 to December 2015, 382 patients
presented to our department with different post-incisional
hernias requiring surgery, and of these, 213 patients
(55.7 %) were previously treated for oncological dis-
eases. In the latter, timing and indications to VH repair
were reviewed by a multidisciplinary team composed by
surgeons, oncologists, radiotherapists, and gastroenter-
ologists considering patient’s characteristics (age and
comorbidities) and clinical symptoms.
One hundred and nine patients (51.2 %) receiving differ-
ent chemotherapy regimens depending on the primitive
disease within 8 weeks from VH repair were selected for
the study and retrospectively analyzed. This time interval
was chosen for the known risk of wound complications
after the use of bevacizumab (AVASTIN, Genentech,
San Francisco, CA) [6]. All patients presented with
symptomatic post-incisional hernias.
Thirty-two patients (31.7 %) were treated with the
placement of a porcine derma-derived biological mesh
(Fortiva® - Tutogen Medical GmbH, Neunkirchen am
Brand, Germany). All patients underwent an open intra-
peritoneal underlay technique; the biological mesh was
placed beyond the fascial edges with a 5-cm minimum
overlap and fixated trans-fascially and circumferentially
using separate monofilament absorbable stitches. Fascial
defect was then re-approximated or closed when feasible
as reinforcement. Two drains were placed subcutane-
ously and removed after 48 h in all cases.
A control group (CG) of patients receiving chemother-
apy within the same time interval, treated with the same
technique but using synthetic intra-peritoneal mesh, was
created with a 1:1 ratio in order to create a case-control
analysis. All patients were defined as American Society
of Anesthesiologists (ASA) score II due to their onco-
logical disease. There were no differences between the two
groups regarding sex, age, number of ASA score III
patients, BMI, and VH size (Table 1). With a median
follow-up (FU) of 24 (7–36) months, all adverse events
were recorded and classified according to the Clavien-Dindo
grade (CD) [12]. Particularly, the presence of wound
dehiscence and seroma (collection with no evidence of
infection) was classified depending on the necessity of
additional use of antibiotics and/or procedures such as
post-operative wound opening, percutaneous drainage,
or operative debridement. Intra-abdominal collections were
defined as abscess whenever fever, leukocytosis, and/or
radiological signs of infection were detected.
Incisional hernia recurrence was defined as a bulge or
defect at the site of VH repair. Patients with clinical
suspect of VH recurrence underwent an abdominal US
and/or CT for confirmation.
Statistical analysis
Continuous variables were presented as mean ± standard
deviation or median (range) when appropriate, and categor-
ical variables were presented as frequency (percentage).
The one-way analysis of variance (ANOVA) test, the
chi-square test, and the Student’s t test were used when
appropriate for comparisons. Univariate and multivariate
analyses were performed through a stepwise logistic re-
gression model using morbidity as a dependent variable.
Statistical analysis was carried out using SPSS software
(Version 20.0. Armonk, NY: IBM Corp) for MacOsX. The
significance level was set at p < 0.05.
Results
Thirty-five out of 64 patients were male (54.7 %), the
mean age was of 58.8 ± 4.6 years old and the mean BMI






Sex (M/F) 18/14 17/15 1
Pathology (colon/ovarian) 25/7 27/5 1
Bevacizumab (n) 3/32 3/32 1
Age (years) 58.63 ± 4.8 59.13 ± 4.4 0.70
Defect size (cm) 7.47 ± 3 7.64 ± 2.5 0.83
BMI (kg/m2) 25.4 ± 3.1 25.6 ± 2.3 0.80
ASA score III 46.8 % (15/32) 53.1 % (17/32) 0.77
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of 25.5 ± 2.8. All patients were defined as ASA score II
due to their oncological history, and 50 % of them (n =
32/64) were ASA III due to their additional comorbidities
such as hypertension in 20 patients (62.5 %), chronic ob-
structive pulmonary disease (COPD) in eight patients
(25 %), and diabetes in six patients (18.7 %).
Fifty-two of the 64 patients (81.3 %) had VH following
previous surgery for colorectal cancer while 12 (18.7 %)
for ovarian cancer; these were equally distributed among
the study groups. Patients’ characteristics are depicted
in Table 1.
The most common chemotherapy regimen adminis-
tered for colorectal cancer was FOLFOX (31/52, 59.6 %);
six (11.5 %) received bevacizumab for the presence of
liver metastases. All patients with ovarian cancer re-
ceived Taxol and carboplatin.
Mean post-operative length of stay was 4.1 ± 0.6 days
in the BIOMESH group and 4.3 ± 1.1 days in the CG
(p = 0.6).
In the BIOMESH group, eight patients (25 %) experi-
enced complications with a mean Clavien-Dindo grade
of 1.67 ± 0.51 (Table 2). Wound dehiscence occurred in
four out of 32 patients (12.5 %) after a mean of 6.7 ±
1.5 days from the operation and were treated conserva-
tively. Resolution was obtained after a mean of 6.6 ± 0.6 days
of treatment. Only three patients (9.3 %) experienced a
small wound seroma not necessitating treatment.
The CG had a significant higher morbidity rate com-
pared with the BIOMESH group (n = 17/32, 53.1 % vs
n = 8/32 25 %; p = 0.02) with a higher, although not sta-
tistically significant, mean Clavien-Dindo grade (1.94 ±
0.44 vs 1.63 ± 0.52; p = 0.13). The incidence of wound
dehiscence was higher in the CG (n = 9/32, 28.1% vs n =
4/32, 12.5%; p = 0.11) although not statistically significant;
the latter were treated conservatively with complete reso-
lution after 6.8 ± 0.7 mean days of treatment. Five patients
(15.6 %) developed subcutaneous seroma after 7.5 ± 0.6
mean days from the operation treated by drainage
through wound opening. One patient experienced an
intra-abdominal collection after 3 days from the oper-
ation treated by percutaneous drainage.
At the univariate analysis, the use of synthetic mesh,
BMI, age >60 years old, and ASA III were predictive factors
of post-operative complications (Table 3). Multivariate
analysis was performed using significant predictive fac-
tors at the univariate analysis. BMI, use of synthetic
mesh, and ASA III were confirmed as predictive factors
of post-operative complications.
After a median follow-up of 24 months (7–36), no pa-
tients in the BIOMESH group developed VH recurrence.
In the CG, two patients out of 32 (6.3 %) presented a
VH recurrence after a mean of 15 ± 1.4 months from the
initial repair. In these patients, the diagnosis of recur-
rence was clinically suspected and confirmed by a CT
scan. These two patients were previously treated with
FOLFOX within a mean of 5.5 ± 0.7 weeks from surgery,
and only one patient received bevacizumab additionally.
No surgical repair of the recurrence was performed in
these patients.
Discussion
Post-operative incisional hernia is the most common
long-term complication after abdominal surgery; world-
wide consensus concerning optimal timing and surgical
strategy is currently lacking; therefore, post-operative VH
still represents a challenging issue for surgeons [13, 14].
The use of prosthesis is nowadays considered as a gold
standard due to the lower rate of recurrences compared to
direct tissue repair. However, currently used meshes such
as polypropylene or GORE-TEX can cause adhesions, fis-
tulae, wound infections, mesh contraction and migration,
seroma, and chronic pain [9, 15–18]. Furthermore, recur-
rence rate following VH repair with mesh still represents
an issue reaching a rate of 10 % in some series [19]. The
incidence of post-operative complications and recurrence
is based on a multifactorial etiology: patients’ charac-
teristics, comorbidities (such as COPD and diabetes),
and technical aspects (technique, site of mesh place-
ment, and type of mesh used) [4, 5]. In this setting,
chemotherapy has been identified as a risk factor for
complications and recurrence due to the consequent
immunosuppression [6, 7].
The recent diffusion of biologic materials-based meshes
has lowered infection rates and overall complication rates
in high-risk patients [3, 11]. For these reasons, we per-
formed this retrospective study to evaluate the usefulness
and safety of the use of BIOMESH in high-risk patients
who underwent chemotherapy in a short time frame.
Table 2 Post-operative complications
Type of complications BIOMESH group n = 32 CD grade Control group n = 32 CD grade p
Complications 25 % (8/32) 53.1 % (17/32) 0.02
Wound dehiscence 12.5 % (4/32) 2 28.1 % (9/32) 2 0.11
Seroma 9.3 % (3/32) 1 15.6 % (5/32) 2 0.35
Intra-abdominal collection 0 % (0/32) – 3.1 % (1/32) 3 –
Subcutaneus hematoma 6.2 % (2/32) 2 9.4 % (3/32) 2 1
Mean Clavien-Dindo grade 1.63 ± 0.52 1.97 ± 0.44 0.13
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Considering the two group’s homogeneity regarding
important risk factors such as BMI, ASA score III, age,
size of the VH defect, and pathology, we observed a
statistically significant lower incidence of post-operative
complications in the BIOMESH group. These better
short-term outcomes are probably related to the intrinsic
characteristic of the porcine BIOMESH which provides a
collagen and extracellular matrix scaffold in which the
host fibroblast enhances angiogenesis and deposits new
collagen resulting in a lower risk of infection, erosion, and
rejection [9, 20–22]. In patients who underwent chemo-
therapy, in which the presence of immunosuppression has
a negative impact on mesh incorporation, these are crucial
aspects to consider. The non-synthetic nature of these
prostheses certainly play a role in diminishing the rate of
post-operative infections.
After a median follow-up of 24 months (7–36), no pa-
tients in the BIOMESH group developed a recurrence
while two patients in the CG were clinically and radio-
logically diagnosed with a recurrence. This result should
be strengthened by a study with a bigger sample size
and a longer follow-up.
Our univariate analysis concerning the impact of different
factors on the development of complications, in addition to
confirm age, BMI, defect size, and ASA score III as
well-known predictors of morbidity, demonstrated that
the use of BIOMESH was protective for these high-risk
patients. These results were subsequently confirmed at
the multivariate analysis.
The small number of patients certainly represents the
main limit of this study. For this reason, the impact of
bevacizumab administration on post-operative outcomes
was not investigated; only six patients equally distrib-
uted between the two groups underwent bevacizumab-
associated therapy, and only one developed a recurrence.
On the other hand, it has to be considered that patients
undergoing VH repair in a short time frame from chemo-
therapy are highly selected: specifically, it is commonly
considered that patients should undergo surgery after
an adequate time interval from chemotherapy, in order
to reach an appropriate compliance of the patient, im-
proving post-operative results. Despite this, in patients
with symptomatic VH, surgical treatment represents
the only option. After a careful multidisciplinary evalu-
ation, we enrolled 64 patients, and to our knowledge,
this represents the largest case-controlled study available
in literature concerning VH repair in these highly selected
patients. On the other hand, this could result in a pos-
sible selection bias certainly influencing positively our
post-operative results due to the selected pool of patients.
However, this process could be, in our opinion, hardly
avoided due to the particular condition and surgical indi-
cation of these patients.
Unfortunately, cost evaluation was not performed in
our study due to the lack of data. The retrospective
fashion of the study is another limit; certainly, a prospect-
ive randomized study could improve and strengthen our
results.
Conclusions
In conclusion, post-incisional ventral hernia repair still
represents a challenge for surgeons due to the risk of
wound dehiscence and recurrence related to different
technical aspects and patient characteristics. The use of
biological meshes could be considered a valid option to
improve post-operative short-term outcomes in selected
high-risk patients undergoing chemotherapy.
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